Structure Therapeutics reported mid‑stage results showing its oral GLP‑1 candidate produced substantial weight loss—placebo‑adjusted averages in double‑digits at extended timepoints—putting the pill in competitive range with leading injectables. Company data showed up to ~11.3% placebo‑adjusted reduction at roughly eight months and higher losses at escalated doses. However, the trials also recorded high rates of gastrointestinal adverse events: substantial proportions of treated patients experienced nausea and vomiting, and discontinuations occurred in some cohorts. STAT and company releases highlighted efficacy numbers alongside the tolerability profile. Investors have reacted to the efficacy while analysts flagged the safety profile as a potential barrier to adoption and regulatory review; further dose‑optimization and longer follow‑up were cited as next steps.